Retia Medical Welcomes Christopher Benassi to Its Strategic Advisory Board in 2026
In a significant move for its strategic direction, Retia Medical has announced the appointment of Christopher Benassi to its Strategic Advisory Board. This decision comes at a crucial time as the company seeks to enhance its cardiovascular intelligence platform, particularly following its recent FDA 510(k) clearance for the Argos Infinity software.
Christopher Benassi, who previously served as Vice President of the Connected Care Group at Baxter International, brings over 15 years of extensive experience in healthcare and medical technology. His expertise spans across connected care solutions, commercial strategies, mergers and acquisitions, and corporate venture capital. Benassi's appointment signals Retia Medical's commitment to building a robust advisory team capable of navigating the complexities of the healthcare technology landscape.
Retia Medical's recent progression includes the successful clearance from the FDA for its Argos Infinity platform in February 2026. The company has been making headway with commercial deployments in virtual and tele-ICU environments at prominent hospitals, and is in the midst of expanding its reach internationally. Retia's revenue has surged sixfold over the last two years, fueled by its partnership with Medtronic for the Argos Cardiac Output Monitor and the direct commercialization of the Argos Infinity platform.
Having a well-established background in the healthcare field, Benassi is poised to make a notable impact on Retia’s strategic growth. His previous roles not only at Baxter but also in investment banking with firms like Goldman Sachs and UBS, provide him with a unique perspective on healthcare investments and strategy. Notably, he has previously sat on boards and advisory panels for healthcare technology companies, such as Pieces Technologies, which was acquired by SmarterDx, showcasing his ability to contribute at multiple levels in the industry.
"Having spent years at the forefront of connected care, I've seen firsthand what it takes to build a durable software and monitoring franchise," Benassi stated, expressing his excitement about joining Retia Medical. He is particularly impressed with the clinical evidence and regulatory achievements that Retia has accomplished, highlighting its differentiated position in the market. Benassi added, "I believe the most important chapter of this company is still ahead."
Marc Zemel, Co-Founder and CEO of Retia Medical, emphasized the value that Benassi brings to the company. He remarked on Benassi’s leadership experience in managing a significant connected care business and how his understanding of the market's commercial and strategic dimensions aligns perfectly with Retia’s growth goals.
Retia Medical specializes in developing cardiovascular intelligence software that translates routine physiological monitoring data into actionable insights for clinical use. The Argos Infinity platform, which is the latest innovation from Retia, operates as a Software as a Medical Device (SaMD) solution capable of integrating with existing bedside and tele-ICU infrastructures. This capability enhances the delivery of scalable clinical insights into cardiovascular status, allowing healthcare providers to proactively detect and manage cardiovascular conditions, leading to improved patient outcomes.
Currently headquartered in White Plains, NY, Retia Medical continues to innovate within the sphere of healthcare technology. Its ambition to further the development of its algorithms, which are currently protected by multiple patents, positions the company as a key player in the market. As they expand their international footprint, the appointment of strategic leaders like Benassi reflects their commitment to pioneering advancements in cardiovascular care, leveraging technology to improve patient monitoring and management on a global scale. For further information about Retia Medical and its innovations, you can visit their official website at www.retiamedical.com.
Christopher Benassi, who previously served as Vice President of the Connected Care Group at Baxter International, brings over 15 years of extensive experience in healthcare and medical technology. His expertise spans across connected care solutions, commercial strategies, mergers and acquisitions, and corporate venture capital. Benassi's appointment signals Retia Medical's commitment to building a robust advisory team capable of navigating the complexities of the healthcare technology landscape.
Retia Medical's recent progression includes the successful clearance from the FDA for its Argos Infinity platform in February 2026. The company has been making headway with commercial deployments in virtual and tele-ICU environments at prominent hospitals, and is in the midst of expanding its reach internationally. Retia's revenue has surged sixfold over the last two years, fueled by its partnership with Medtronic for the Argos Cardiac Output Monitor and the direct commercialization of the Argos Infinity platform.
Having a well-established background in the healthcare field, Benassi is poised to make a notable impact on Retia’s strategic growth. His previous roles not only at Baxter but also in investment banking with firms like Goldman Sachs and UBS, provide him with a unique perspective on healthcare investments and strategy. Notably, he has previously sat on boards and advisory panels for healthcare technology companies, such as Pieces Technologies, which was acquired by SmarterDx, showcasing his ability to contribute at multiple levels in the industry.
"Having spent years at the forefront of connected care, I've seen firsthand what it takes to build a durable software and monitoring franchise," Benassi stated, expressing his excitement about joining Retia Medical. He is particularly impressed with the clinical evidence and regulatory achievements that Retia has accomplished, highlighting its differentiated position in the market. Benassi added, "I believe the most important chapter of this company is still ahead."
Marc Zemel, Co-Founder and CEO of Retia Medical, emphasized the value that Benassi brings to the company. He remarked on Benassi’s leadership experience in managing a significant connected care business and how his understanding of the market's commercial and strategic dimensions aligns perfectly with Retia’s growth goals.
Retia Medical specializes in developing cardiovascular intelligence software that translates routine physiological monitoring data into actionable insights for clinical use. The Argos Infinity platform, which is the latest innovation from Retia, operates as a Software as a Medical Device (SaMD) solution capable of integrating with existing bedside and tele-ICU infrastructures. This capability enhances the delivery of scalable clinical insights into cardiovascular status, allowing healthcare providers to proactively detect and manage cardiovascular conditions, leading to improved patient outcomes.
Currently headquartered in White Plains, NY, Retia Medical continues to innovate within the sphere of healthcare technology. Its ambition to further the development of its algorithms, which are currently protected by multiple patents, positions the company as a key player in the market. As they expand their international footprint, the appointment of strategic leaders like Benassi reflects their commitment to pioneering advancements in cardiovascular care, leveraging technology to improve patient monitoring and management on a global scale. For further information about Retia Medical and its innovations, you can visit their official website at www.retiamedical.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.